TEVA PHARMACEUTICAL INDS LTD's ticker is TEVA and the CUSIP is 881624209. A total of 822 filers reported holding TEVA PHARMACEUTICAL INDS LTD in Q2 2015. The put-call ratio across all filers is 0.72 and the average weighting 0.6%.
About TEVA PHARMACEUTICAL INDS LTD
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that specializes in the development, production, and marketing of generic and specialty medicines. The company is headquartered in Israel and has operations in over 60 countries worldwide.
Teva has a diverse portfolio of products that includes treatments for a wide range of medical conditions, including respiratory, neurological, and oncological diseases. The company is also a leading producer of generic drugs, which are more affordable alternatives to brand-name medications.
In recent years, Teva has faced a number of challenges, including increased competition in the generic drug market and a decline in sales of its flagship product, Copaxone, which is used to treat multiple sclerosis. However, the company has taken steps to address these issues, including restructuring its operations and investing in research and development to bring new products to market.
Despite these challenges, Teva remains a major player in the pharmaceutical industry, with a strong global presence and a commitment to improving the health and well-being of patients around the world. As the company continues to evolve and adapt to changing market conditions, it will be interesting to see what the future holds for this innovative and dynamic organization.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $77,180,842 | +2512.0% | 4,749,590 | +2168.0% | 0.02% | +1500.0% |
| Q1 2024 | $2,954,903 | +34.7% | 209,419 | -0.3% | 0.00% | 0.0% |
| Q4 2023 | $2,193,695 | -1.7% | 210,124 | -4.0% | 0.00% | 0.0% |
| Q3 2023 | $2,232,768 | +37.1% | 218,899 | +1.2% | 0.00% | – |
| Q2 2023 | $1,629,056 | -31.0% | 216,342 | -18.9% | 0.00% | -100.0% |
| Q1 2023 | $2,360,224 | -32.0% | 266,692 | -30.0% | 0.00% | 0.0% |
| Q4 2022 | $3,472,760 | +13.8% | 380,785 | +0.7% | 0.00% | 0.0% |
| Q3 2022 | $3,051,000 | +11.5% | 378,142 | +3.9% | 0.00% | 0.0% |
| Q2 2022 | $2,736,000 | -16.4% | 363,911 | +4.3% | 0.00% | 0.0% |
| Q1 2022 | $3,274,000 | +18.6% | 348,795 | +1.2% | 0.00% | 0.0% |
| Q4 2021 | $2,761,000 | -61.2% | 344,698 | -52.8% | 0.00% | -50.0% |
| Q3 2021 | $7,115,000 | -25.6% | 730,483 | -24.4% | 0.00% | 0.0% |
| Q2 2021 | $9,569,000 | -4.4% | 966,324 | +11.4% | 0.00% | -33.3% |
| Q1 2021 | $10,011,000 | -32.8% | 867,493 | -43.8% | 0.00% | -25.0% |
| Q4 2020 | $14,901,000 | +23.3% | 1,544,125 | +15.1% | 0.00% | 0.0% |
| Q3 2020 | $12,090,000 | -46.3% | 1,341,737 | -26.5% | 0.00% | -50.0% |
| Q2 2020 | $22,499,000 | +23.1% | 1,824,710 | -10.3% | 0.01% | 0.0% |
| Q1 2020 | $18,274,000 | +323.4% | 2,034,916 | +362.0% | 0.01% | +700.0% |
| Q4 2019 | $4,316,000 | +272.4% | 440,475 | +161.4% | 0.00% | – |
| Q3 2019 | $1,159,000 | +5.9% | 168,494 | +42.1% | 0.00% | – |
| Q2 2019 | $1,094,000 | +26.9% | 118,576 | +115.6% | 0.00% | – |
| Q1 2019 | $862,000 | +38.8% | 54,991 | +36.6% | 0.00% | – |
| Q4 2018 | $621,000 | -39.4% | 40,261 | -15.3% | 0.00% | – |
| Q3 2018 | $1,024,000 | -47.4% | 47,558 | -40.6% | 0.00% | -100.0% |
| Q2 2018 | $1,945,000 | -5.0% | 80,017 | -33.2% | 0.00% | 0.0% |
| Q1 2018 | $2,047,000 | -95.3% | 119,807 | -94.7% | 0.00% | -93.8% |
| Q4 2017 | $43,100,000 | -80.0% | 2,274,429 | -81.4% | 0.02% | -79.7% |
| Q3 2017 | $215,018,000 | -56.1% | 12,216,902 | -17.1% | 0.08% | -48.0% |
| Q2 2017 | $489,494,000 | +3.1% | 14,734,874 | -0.4% | 0.15% | -2.6% |
| Q1 2017 | $474,967,000 | -11.9% | 14,801,119 | -0.4% | 0.16% | -13.8% |
| Q4 2016 | $538,899,000 | -18.1% | 14,866,203 | +3.9% | 0.18% | -19.9% |
| Q3 2016 | $658,334,000 | -11.6% | 14,308,522 | -3.5% | 0.23% | -17.5% |
| Q2 2016 | $744,844,000 | -26.4% | 14,828,675 | -21.6% | 0.27% | -33.3% |
| Q1 2016 | $1,011,656,000 | -20.3% | 18,905,926 | -2.3% | 0.41% | -18.9% |
| Q4 2015 | $1,269,839,000 | +16.5% | 19,345,501 | +0.2% | 0.51% | +9.7% |
| Q3 2015 | $1,089,697,000 | -12.5% | 19,300,324 | -8.4% | 0.46% | -5.5% |
| Q2 2015 | $1,245,293,000 | -9.6% | 21,070,949 | -4.7% | 0.49% | -8.3% |
| Q1 2015 | $1,377,869,000 | +17.3% | 22,116,690 | +8.3% | 0.53% | +17.4% |
| Q4 2014 | $1,174,644,000 | +9.7% | 20,425,021 | +2.5% | 0.45% | +6.1% |
| Q3 2014 | $1,071,240,000 | +4.1% | 19,930,062 | +1.5% | 0.43% | +5.7% |
| Q2 2014 | $1,028,835,000 | +33.2% | 19,626,769 | +34.2% | 0.40% | +29.4% |
| Q1 2014 | $772,626,000 | +88.2% | 14,621,995 | +42.7% | 0.31% | +92.0% |
| Q4 2013 | $410,571,000 | -24.5% | 10,243,751 | -28.8% | 0.16% | -30.9% |
| Q3 2013 | $543,709,000 | +14.1% | 14,391,455 | +18.4% | 0.24% | +6.3% |
| Q2 2013 | $476,431,000 | – | 12,153,843 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Noked Israel Ltd | 2,956,700 | $36,456,000 | 26.07% |
| Noked Capital LTD | 2,956,700 | $36,456,000 | 26.07% |
| Southpaw Asset Management LP | 717,100 | $8,842,000 | 21.91% |
| Ion Asset Management Ltd. | 5,176,190 | $63,822,000 | 10.69% |
| Abrams Capital Management | 24,046,356 | $296,492,000 | 9.58% |
| Phoenix Financial Ltd. | 11,684,589 | $136,791,000 | 5.80% |
| MENORA MIVTACHIM HOLDINGS LTD. | 17,925,000 | $221,015,000 | 5.42% |
| Migdal Insurance & Financial Holdings Ltd. | 21,872,990 | $269,694,000 | 4.38% |
| MILLER VALUE PARTNERS, LLC | 7,850,472 | $96,796,000 | 4.30% |
| Clal Insurance Enterprises Holdings Ltd | 16,418,571 | $202,441,000 | 4.01% |